<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03317392</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2017-01920</org_study_id>
    <secondary_id>NCI-2017-01920</secondary_id>
    <secondary_id>10096</secondary_id>
    <secondary_id>10096</secondary_id>
    <secondary_id>UM1CA186689</secondary_id>
    <secondary_id>UM1CA186709</secondary_id>
    <nct_id>NCT03317392</nct_id>
  </id_info>
  <brief_title>Olaparib and Radium Ra 223 Dichloride in Treating Men With Metastatic Castration-Resistant Prostate Cancer That Has Spread to the Bone</brief_title>
  <official_title>A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the best dose and side effects of olaparib and how well it
      works with radium Ra 223 dichloride in treating patients with castration-resistant prostate
      cancer that has spread to the bone and other places in the body (metastatic). Olaparib may
      stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
      Radioactive drugs, such as radium Ra 223 dichloride, may carry radiation directly to tumor
      cells and not harm normal cells. Giving olaparib and radium Ra 223 dichloride may work better
      at treating castration-resistant prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Determine the maximum tolerated dose (MTD) of olaparib in combination with radium Ra 223
      dichloride (radium-223). (Phase 1) II. Evaluate the radiographic progression-free survival
      (rPFS). (Phase 2)

      SECONDARY OBJECTIVES:

      I. Evaluate safety and tolerability as assessed by Common Terminology Criteria for Adverse
      Events (CTCAE) version 5.0.

      II. To evaluate rPFS as stratified by disease extent (=&lt; 20 or &gt; 20 bone lesions) and prior
      docetaxel use (yes or no).

      III. Evaluate rPFS in patients harboring or lacking evidence of homologous recombination
      deficiency (HRD) IV. Evaluate rPFS in patients based on prior abiraterone and/or next
      generation androgen receptor (AR) antagonist (enzalutamide, apalutamide, darolutamide or
      other agent) use (yes versus no) for either hormone sensitive or castration resistant
      prostate cancer (CRPC).

      V. Evaluate prostate specific antigen (PSA) response rate as defined by &gt;= 50% decline in PSA
      from baseline.

      VI. Evaluate total alkaline phosphatase response defined as a reduction of &gt;= 30% from the
      baseline value, confirmed &gt;= 4 weeks later.

      VII. Evaluate time to PSA progression as defined by Prostate Cancer Clinical Trials Working
      Group (PCTWG) 3 criteria.

      VIII. Evaluate radiographic objective response rate as defined by Response Evaluation
      Criteria in Solid Tumor (RECIST) version 1.1.

      IX. Evaluate time to increase in the total alkaline phosphatase (ALP) level defined as an
      increase of &gt;= 25% from baseline at &gt;= 12 weeks, in patients with no decrease from baseline,
      or as an increase of &gt;= 25% above the nadir, confirmed &gt;= 3 weeks later, in patients with an
      initial decrease from baseline.

      X. Evaluate time to initiation of next active anti-cancer therapy (including AR signaling
      agents, cytotoxic chemotherapy, immunotherapy, or investigational agents).

      XI. Evaluate time to first symptomatic skeletal event (SSE). XII. Evaluate overall survival
      (OS).

      EXPLORATORY OBJECTIVES:

      I. Evaluate impact on quality of life (QOL) as determined by Functional Assessment of Cancer
      Therapy-Prostate (FACT-P) questionnaire and Brief Pain Inventory (BPI).

      II. Estimate the frequency of mutations in the deoxyribonucleic acid (DNA) repair pathway in
      patients with metastatic castration-resistant prostate cancer (CRPC) as determine by
      Oncopanel testing and by whole exome sequencing (WES).

      III. Characterize changes in ribonucleic acid (RNA) expression of DNA repair genes and immune
      markers by whole transcriptome sequencing (WTS) in each arm.

      IV. Characterize changes in immune cell, T-cell receptor (TCR), and B-cell (BCR) receptor
      repertoire at baseline, during treatment, and at progression in each arm.

      V. Evaluate changes in lactate dehydrogenase (LDH) in patients each treatment arm.

      VI. Assess the prevalence of germline mutations in homologous recombination genes in all
      enrolled patients.

      VII. Correlate homologous recombination gene germline mutation status with PSA response by
      treatment arm.

      VIII. Evaluate family history of cancers in the study population and correlate family cancer
      history with germline mutation status.

      IX. Correlate presence or absence of RAD51 with somatic and germline homologous recombination
      gene mutation status, PSA response, and PFS between treatment arms.

      X. Evaluate the changes in whole genome sequencing (WGS) of plasma cell-free circulating DNA
      (cfDNA) based patient-tumor specific signature at baseline, on treatment, and at progression.

      XI. Evaluate tumor mutation burden (TMB) and tumor mutational signature in plasma cfDNA at
      baseline and correlate to tumor tissue TMB and mutational signature.

      OUTLINE: This is a phase I, dose-escalation study of olaparib followed by a phase II study.

      PHASE I: Patients receive radium Ra 223 dichloride intravenously (IV) over 1 minute on day 1.
      Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or
      unacceptable toxicity. Patients also receive olaparib orally (PO) twice daily (BID) on days
      1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable
      toxicity.

      PHASE II: Patients are randomized to 1 of 2 arms.

      ARM I: Patients receive radium Ra 223 dichloride IV over 1 minute on day 1. Treatment repeats
      every 28 days for up to 6 cycles in the absence of disease progression or unacceptable
      toxicity. Patients also continue to receive olaparib as in Phase I.

      ARM II: Patients receive radium Ra 223 dichloride as in Arm I.

      After completion of study treatment, patients are followed up every 6 months for 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 12, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of olaparib and radium Ra 223 dichloride</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiographic progression-free survival (rPFS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be estimated using the Kaplan-Meier method by treatment arm. A stratified Cox proportional hazards regression model will estimate the rPFS treatment hazard ratio with 80% 2-sided confidence intervals (CIs).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiographic progression free survival (rPFS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Treatment comparison in rPFS will be conducted in pre-defined subgroups, including homologous recombination deficiency status (yes/no), disease extent (=&lt; 20 or &gt; 20 bone lesions) and prior docetaxel (yes or no). Cox regression hazard ratios (for treatment comparison) along two-sided 80% CI will be provided for each subgroup.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate specific antigen (PSA) response defined by 50% decline in PSA from baseline</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Response rate by different criteria will be summarized as number and percentage of participants by treatment arm with two-sided 80% CI and compared between groups using Fisher's exact tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alkaline phosphatase (ALP) response defined as &gt;= 30% reduction of the blood level, compared to the baseline value</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be assessed by RECIST 1.1. Response rate by different criteria will be summarized as number and percentage of participants by treatment arm with two-sided 80% CI and compared between groups using Fisher's exact tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be assessed by RECIST 1.1. Response rate by different criteria will be summarized as number and percentage of participants by treatment arm with two-sided 80% CI and compared between groups using Fisher's exact tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate specific antigen (PSA) progression</measure>
    <time_frame>From randomization to PSA progression by Prostate Cancer Working Group (PCWG) 3 criteria, assessed up to 2 years</time_frame>
    <description>Will be estimated using the method of Kaplan-Meier and compared between treatment arms using the stratified log-rank test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALP progression</measure>
    <time_frame>From randomization to the date of first ALP progression, assessed up to 2 years</time_frame>
    <description>Will be estimated using the method of Kaplan-Meier and compared between treatment arms using the stratified log-rank test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic skeletal event (SSE)</measure>
    <time_frame>From randomization to occurrence of the first SSE, such as pathologic bone fracture, spinal cord compression, hypercalcemia of malignancy or radiation therapy or surgery to bone, described by the US Food and Drug Administration, assessed up to 2 years</time_frame>
    <description>Will be estimated using the method of Kaplan-Meier and compared between treatment arms using the stratified log-rank test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From randomization to the date of death due to any cause, assessed up to 2 years</time_frame>
    <description>Will be estimated using the method of Kaplan-Meier and compared between treatment arms using the stratified log-rank test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 5. Adverse events will be summarized according to grade, overall and by treatment arm, as number and percentage of participants. All adverse events resulting in discontinuation, dose modification, and/or dosing interruption, and/or treatment delay of drug will also be summarized by treatment arm.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in levels of serum lactate dehydrogenase (LDH)</measure>
    <time_frame>Baseline up to 2 years</time_frame>
    <description>Will be summarized at baseline and each cycle with descriptive statistics. Percent change from baseline or status change (e.g. from normal to abnormal defined by institution upper limit level) will be reported and compared between treatment arms at selected timepoints using Wilcoxon rank sum test or Fisher's exact test as appropriate.</description>
  </other_outcome>
  <other_outcome>
    <measure>Frequency of mutations in the deoxyribonucleic acid (DNA) repair pathway</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be determined by Oncopanel testing. Gene mutation frequencies and mean +/- standard deviation of quantitative biomarkers will be summarized by arm and in overall population at baseline and/or at time of progression.</description>
  </other_outcome>
  <other_outcome>
    <measure>Homologous recombination deficiency</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Cox regression or logistic regression will be conducted to explore the association of rPFS or treatment response (PSA or tumor response) with homologous recombination gene mutation status.</description>
  </other_outcome>
  <other_outcome>
    <measure>Prevalence of germline mutations in homologous recombination genes</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Their correlation with family history of cancers as determined by the Family History Questionnaire and PSA response will be evaluated using Fisher's exact test or logistic regression as appropriate in all patients and/or by treatment arm as exploratory analyses.</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life (QOL)</measure>
    <time_frame>Baseline up to 2 years</time_frame>
    <description>Will be measured using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire and Brief Pain Inventory (BPI). For each treatment group, calculated QOL scores will be summarized at baseline and each time point. Changes from baseline will be graphically presented. The effect of treatment will be evaluated using a repeated measures model to incorporate assessments across time into a single analysis, using model contrasts to compare treatment groups at selected time points.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Castration-Resistant Prostate Carcinoma</condition>
  <condition>Metastatic Prostate Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Arm I (radium Ra 223 dichloride, olaparib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive radium Ra 223 dichloride IV over 1 minute on day 1. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also continue to receive olaparib PO BID as in Phase I.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (radium Ra 223 dichloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive radium Ra 223 dichloride as in Arm I.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (radium Ra 223 dichloride, olaparib)</arm_group_label>
    <arm_group_label>Arm II (radium Ra 223 dichloride)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaparib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (radium Ra 223 dichloride, olaparib)</arm_group_label>
    <other_name>AZD 2281</other_name>
    <other_name>AZD-2281</other_name>
    <other_name>AZD2281</other_name>
    <other_name>KU-0059436</other_name>
    <other_name>Lynparza</other_name>
    <other_name>PARP Inhibitor AZD2281</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radium Ra 223 Dichloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (radium Ra 223 dichloride, olaparib)</arm_group_label>
    <arm_group_label>Arm II (radium Ra 223 dichloride)</arm_group_label>
    <other_name>Alpharadin</other_name>
    <other_name>BAY 88-8223</other_name>
    <other_name>BAY88-8223</other_name>
    <other_name>Radium 223 Dichloride</other_name>
    <other_name>RADIUM RA-223 DICHLORIDE</other_name>
    <other_name>Radium-223 Dichloride</other_name>
    <other_name>Xofigo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must have histologically or cytologically confirmed adenocarcinoma of the
             prostate

          -  Participants must have castrate levels of serum testosterone &lt; 50 ng/dL

          -  Participants without orchiectomy must be maintained on luteinizing hormone releasing
             hormone (LHRH) agonist/antagonist; participants receiving prior docetaxel abiraterone,
             or next generation AR antagonist (enzalutamide, apalutamide, or darolutamide) for
             hormone sensitive disease are permitted

          -  Participants must have progressive disease as defined by any of the following:

               -  Castrate resistant disease as defined by PCWG-3 criteria; participants must have
                  a rise in PSA on two successive determination at least one week apart and PSA
                  levels &gt;= 2 ng/mL (only the screening PS needs to be &gt;= 2 ng/mL) and serum
                  testosterone &lt; 50 ng/dL

               -  Soft tissue progression as defined by RECIST version 1.1

               -  Bone disease progression as defined by PCWG-3 criteria including the development
                  of two or more new lesions on bone scan

          -  Participants must have &gt;= 2 bone metastases by radiographic imaging and at least 1
             lesion which has not been treated with prior radiation therapy

          -  Participants must have tumor accessible for biopsy and be agreeable to baseline tumor
             biopsy; a metastatic focus is preferred but if not available and prostate is still
             intact prostate biopsy can be performed

          -  Availability at the study site of formalin-fixed, paraffin-embedded (FFPE) archival
             tumor specimens, when available

          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 1 (Karnofsky &gt;= 80%)

          -  White blood cell count (WBC) &gt;= 3,000/mcL (within 28 days prior to administration of
             study treatment)

          -  Absolute neutrophil count (ANC) &gt;= 1,500/mcL (within 28 days prior to administration
             of study treatment)

          -  Platelets &gt;= 100,000/mcL (within 28 days prior to administration of study treatment)

          -  Hemoglobin &gt;= 10 g/dL (transfusions permitted) (within 28 days prior to administration
             of study treatment)

          -  Total bilirubin =&lt; 1.5 x the institutional upper limit of normal (ULN) (within 28 days
             prior to administration of study treatment); for subjects with Gilbert's disease =&lt;
             3.0 mg/dL

          -  Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =&lt; 3 x institutional
             ULN (within 28 days prior to administration of study treatment)

          -  Creatinine clearance &gt;= 51 ml/min as defined by Cockcroft-Gault equation (within 28
             days prior to administration of study treatment)

          -  The effects of olaparib and radium-223 on the developing human fetus are unknown; for
             this reason, men treated or enrolled on this protocol must agree to use adequate
             contraception and avoid sperm donation prior to the study, for the duration of study
             participation, and three months after discontinuation of olaparib and radium-223
             administration

          -  Human immunodeficiency virus (HIV)-positive with negative viral loads on stable
             antiretroviral regimen and CD4 count &gt; 250 are eligible

          -  Ability to understand and the willingness to sign a written informed consent document;
             patients with impaired decision-making who have a legal guardian (e.g., spouse) able
             to make informed decisions on behalf of the patient are eligible

          -  Patients must be able to tolerate oral medications by mouth and not have a
             gastrointestinal illness that would preclude absorption of olaparib

        Exclusion Criteria:

          -  Pathology consistent with small cell carcinoma of the prostate

          -  Presence of visceral metastases (liver, lung, brain, etc.) or malignant
             lymphadenopathy exceeding 4 centimeters (cm) in short diameter

          -  Prior treatment with radium-223

          -  Prior treatment with olaparib or other PARPi

          -  Treatment with abiraterone, apalutamide, or darolutamide within 2 weeks of treatment
             initiation; treatment with cytotoxic chemotherapy within 3 weeks of treatment
             initiation; treatment with investigational prostate cancer directed therapy within 4
             weeks of treatment initiation; treatment with enzalutamide within 4 weeks of treatment
             initiation

          -  Prior hemibody external radiotherapy

          -  Palliative radiation therapy to the bone or other sites within 2 weeks of treatment
             initiation

          -  Participants who are receiving any other investigational agents

          -  Imminent or established spinal cord compression based on clinical and/or imaging
             findings

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection requiring need for intravenous anti-microbials, symptomatic congestive heart
             failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social
             situations that would limit compliance with study requirements

          -  Clinically significant medical condition defined as:

               -  Cerebral infarction within 6 months of study treatment

               -  Transient ischemic attack within 3 months of study treatment

               -  Myocardial infarction within 6 months of study treatment

               -  Uncontrolled angina within 3 months of study treatment

               -  Congestive heart failure New York Heart Association (NYHA) class 3 or 4, or
                  subjects with history of congestive heart failure NYHA class 3 or 4 in the past,
                  or history of anthracycline or anthracenedione (mitoxantrone) treatment, unless a
                  screening echocardiogram or multi‚Äêgated acquisition scan performed within 3
                  months of the screening visit results in a left ventricular ejection fraction
                  that is &gt;= 45%

               -  History of clinically significant ventricular arrhythmias (e.g., ventricular
                  tachycardia, ventricular fibrillation, torsade de pointes)

               -  Prolonged corrected QT interval by the Fridericia correction formula on the
                  screening electrocardiogram (ECG) &gt; 470 msec

               -  History of Mobitz II second degree or third degree heart block without a
                  permanent pacemaker in place

               -  Uncontrolled hypertension as indicated by a resting systolic blood pressure &gt; 170
                  mmHg or diastolic blood pressure &gt; 105 mmHg at the screening visit

               -  History of hypertensive emergency or encephalopathy within 6 months of study
                  treatment

               -  Deep venous thrombosis or pulmonary embolism within 3 months of study treatment

          -  Major surgery within 4 weeks of study treatment; subjects with clinically relevant
             ongoing complications from prior surgery are not eligible

          -  History of gastrointestinal disorders (medical disorders or extensive surgery) which
             may interfere with the absorption of the study drug

          -  Patient unable to swallow orally administered medication

          -  History of bowel obstruction within 1 month of study treatment

          -  History of abdominal fistula, intra-abdominal abscess, or gastrointestinal perforation
             within the 3 months of study treatment

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to olaparib or radium-223

          -  Participants receiving strong CYP3A4/5 inducers or inhibitors are ineligible;
             dihydropyridine calcium-channel blockers are permitted for management of hypertension;
             the required washout period prior to starting olaparib is 2 weeks for CYP3A
             inhibitors; the required washout period prior to starting olaparib is 4 weeks for
             enzalutamide or phenobarbital and 3 weeks for other CYP3A inducers

          -  Patients with known active hepatitis (i.e. hepatitis B or C) infection

          -  Patients with myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with
             features suggestive of MDS/AML

          -  Patient having received prior allogenic bone marrow transplant or double umbilical
             cord blood transplantation

          -  Individuals with a history of a different malignancy are ineligible except for the
             following circumstances:

               -  Individuals with a history of other malignancies are eligible if they have been
                  disease-free for at least 3 years and are deemed by the investigator to be at low
                  risk for recurrence of that malignancy, or

               -  Individuals with the following cancers are eligible if diagnosed and treated
                  within the past 5 years: superficial bladder cancer, basal cell or squamous cell
                  carcinoma of the skin
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rana R McKay</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University Cancer Center LAO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>858-822-5354</phone>
      <email>cancercto@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Rana R. McKay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>916-734-3089</phone>
    </contact>
    <investigator>
      <last_name>Mamta Parikh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Center/Yale-New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>203-785-5702</phone>
      <email>canceranswers@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph W. Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>203-785-5702</phone>
      <email>canceranswers@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph W. Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Clinical Research Center</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>913-588-3671</phone>
      <email>KUCC_Navigation@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Rahul A. Parikh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>913-588-3671</phone>
      <email>KUCC_Navigation@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Rahul A. Parikh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Hospital-Westwood Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>913-588-3671</phone>
      <email>KUCC_Navigation@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Rahul A. Parikh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wayne State University/Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>313-576-9790</phone>
      <email>ctoadmin@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Elisabeth I. Heath</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at West County Hospital</name>
      <address>
        <city>Creve Coeur</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-600-3606</phone>
      <email>info@siteman.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Hiram A. Gay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-600-3606</phone>
      <email>info@siteman.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Hiram A. Gay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center-South County</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-600-3606</phone>
      <email>info@siteman.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Hiram A. Gay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at Saint Peters Hospital</name>
      <address>
        <city>Saint Peters</city>
        <state>Missouri</state>
        <zip>63376</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-600-3606</phone>
      <email>info@siteman.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Hiram A. Gay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>732-235-8675</phone>
    </contact>
    <investigator>
      <last_name>Biren Saraiya</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-293-5066</phone>
      <email>Jamesline@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Edmund Folefac</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute (UPCI)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>412-647-8073</phone>
    </contact>
    <investigator>
      <last_name>Adam Olson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 20, 2017</study_first_submitted>
  <study_first_submitted_qc>October 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2017</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olaparib</mesh_term>
    <mesh_term>Poly(ADP-ribose) Polymerase Inhibitors</mesh_term>
    <mesh_term>Radium Ra 223 dichloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

